Company news

Amarantus Bioscience Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan

January 17, 2019

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa

January 15, 2019

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

January 11, 2019

Amarantus Provides 2019 Roadmap

January 7, 2019

Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0

December 3, 2018

Coeptis Pharma Enters into Agreement to Acquire Elto Pharma

November 28, 2018

Withdrawal of JV Offer

October 23, 2018

Term Sheet in Support of JV

October 19, 2018

Joint Venture Offer

October 18, 2018

Amarantus Provides Corporate Update

July 20, 2018

MANF Therapeutics Announces Positive MANF Pre-Clinical Data inAlpha-Synuclein Model of Parkinson's DiseasePublished in Peer-Reviewed Journal Experimental Neurobiology

July 9, 2018

Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"

May 30, 2018

Amarantus to Present at LD Micro and The Reg A Conference

May 24, 2018

Amarantus Retains Weild & Co. to Advise on JOBS Act Funding

May 22, 2018

MANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal Photoreceptor Protection Data for MANF

May 21, 2018

Amarantus Provides Business Overview

May 11, 2018

Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET

May 4, 2018

MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's

May 3, 2018

Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment

May 1, 2018

Elto PharmaAppoints Paula Trzepacz, MD asChief Medical Advisor

April 30, 2018

Cutanogen Appoints Richard Kagan, MD as Chief Medical Advisor

April 23, 2018

Amarantus to Present at the Planet MicroCap Showcase 2018 in Las Vegas

April 19, 2018

Amarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test Program

April 16, 2018

Amarantus to Present at The Microcap Conference in NYC

April 9, 2018

Amarantus Re-acquires Rights to Alzheimer's Blood Diagnostic LymPro Test

April 6, 2018

Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor

April 5, 2018

Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City

April 2, 2018

Amarantus Completes Tender Exchange of Convertible Securities; CEO attending CNBC's Healthy Returns conference in New York City

March 28, 2018

Elto Pharma Receives Notice of Allowance in Australia for Patent Covering Eltoprazine in the Treatment of Parkinson's Levodopa-induced Dyskinesia

March 8, 2018

Elto Pharma to Present and Participate in Neuroscience Panel at Sachs BioCapital USA Forum

March 5, 2018

MANF Therapeutics Announces the Issuance of U.S. Patent #9,891,231

March 1, 2018

Amarantus Enters into Definitive Agreements for up to $1.5 Million in Funding

February 26, 2018

Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease

January 29, 2018

Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

January 23, 2018

Amarantus Provides Update on Capital Restructuring and Announces Participation in RESI JPM 2018

January 9, 2018

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS

January 4, 2018

AMBS Enters into Binding LOI to Re-acquire Rights to LymPro, MSPRecise and NuroPro

January 2, 2018

Amarantus Subsidiary MANF Therapeutics Announces Patent Issuances in Europe and China Covering MANF as a Treatment and Biomarker in Diabetes and Publication of MANF Human Pre-Diabetes and Diabetes Biomarker Data

January 3, 2018

Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma

December 26, 2017

Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease

December 20, 2017

Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF

December 14, 2017

Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes

December 11, 2017

Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID

December 7, 2017

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer’s Disease and Parkinson’s disea

December 6, 2017

Amarantus Provides Comprehensive Corporate Update •

December 6, 2017

Amarantus Enters into Forbearance and Capital Restructuring Agreements with Holders of Secured Debt, Convertible Preferred Stock and Warrants

December 6, 2017

Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology

April 17, 2017

Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.

April 5, 2017

Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.

February 27, 2017

Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld

February 10, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 10 decks. Every deck is listed under its year.